5 New Stock Picks of Billionaire Mario Gabelli

4. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Number of Hedge Fund Holders: 58     

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) develops products for neurological and neuropsychiatric diseases, as well as rare disorders. Securities filings show that GAMCO Investors owned 20,212 shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) at the end of June 2022 worth $2.9 million, representing a small portion of the portfolio. 

On August 18, Piper Sandler analyst Christopher Raymond downgraded Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock to Neutral from Overweight with a price target of $149, noting valuation as one of the primary reasons behind the ratings update. 

At the end of the second quarter of 2022, 58 hedge funds in the database of Insider Monkey held stakes worth $2.5 billion in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), compared to 41 in the preceding quarter worth $1.3 billion.